165 related articles for article (PubMed ID: 10955025)
1. [Osteoporosis-induced fractures. Bisphosphonates lower risk also in the hip].
MMW Fortschr Med; 2000 Jul; 142(30):52-3. PubMed ID: 10955025
[No Abstract] [Full Text] [Related]
2. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
Soen S
Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
[TBL] [Abstract][Full Text] [Related]
3. [A good combination to achieve a reduced number of fractures: bone density measurements, drug therapy and hip protector].
Johnell O; Ljunggren O; Mellström D
Lakartidningen; 2001 Jul; 98(28-29):3204-6. PubMed ID: 11496807
[No Abstract] [Full Text] [Related]
4. Do not use bisphosphonate therapy indefinitely for fracture prevention.
Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
[TBL] [Abstract][Full Text] [Related]
5. [Alendronate also for women without established osteoporosis?].
Klovning A; Norheim OF
Tidsskr Nor Laegeforen; 2000 Apr; 120(11):1347-51. PubMed ID: 10868100
[No Abstract] [Full Text] [Related]
6. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Papapoulos SE
Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931
[No Abstract] [Full Text] [Related]
7. Prevention of osteoporotic hip fracture: global versus high-risk strategies.
Barrett-Connor E; Gore R; Browner WS; Cummings SR
Osteoporos Int; 1998; 8 Suppl 1():S2-7. PubMed ID: 9682789
[No Abstract] [Full Text] [Related]
8. Intervention thresholds for the treatment of osteoporosis: comparison of different approaches to decision-making.
Epstein RS; Feng W; Hirsch LJ; Kelly M
Osteoporos Int; 1998; 8 Suppl 1():S22-7. PubMed ID: 9682793
[No Abstract] [Full Text] [Related]
9. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment using bone mineral density determination.
Lindsay R
Osteoporos Int; 1998; 8 Suppl 1():S28-31. PubMed ID: 9682794
[No Abstract] [Full Text] [Related]
11. Clinical management of osteoporosis.
Mulloy AL; Weinstein RS
J Med Assoc Ga; 1994 Apr; 83(4):227-30. PubMed ID: 8006552
[No Abstract] [Full Text] [Related]
12. The role of markers of bone turnover in the assessment of fracture risk in postmenopausal women.
Delmas PD
Osteoporos Int; 1998; 8 Suppl 1():S32-6. PubMed ID: 9682795
[No Abstract] [Full Text] [Related]
13. [Treating with what? Therapy for how long?].
MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
[No Abstract] [Full Text] [Related]
14. Evidence-based assessment of pharmaceutical interventions.
Melton LJ
Osteoporos Int; 1998; 8 Suppl 1():S17-21. PubMed ID: 9682792
[No Abstract] [Full Text] [Related]
15. [Osteoporosis. Fracture as alarm signal].
MMW Fortschr Med; 2001 Oct; 143(41):56. PubMed ID: 11721665
[No Abstract] [Full Text] [Related]
16. [Drug therapy of osteoporosis].
Syversen U; Halse JI
Tidsskr Nor Laegeforen; 2003 Aug; 123(16):2263-4. PubMed ID: 14508549
[No Abstract] [Full Text] [Related]
17. Clinical inquiries. What is the best approach to prevention and treatment of osteoporosis?
Schwartz K; Chang SI
J Fam Pract; 2001 Dec; 50(12):1024-5. PubMed ID: 11742601
[No Abstract] [Full Text] [Related]
18. [Therapy of osteoporosis. Risk factors alone are not an indication].
MMW Fortschr Med; 2001 Dec; 143(49-50):57. PubMed ID: 11813710
[No Abstract] [Full Text] [Related]
19. [Glucocorticoid-induced osteoporosis. Occurrence, prophylaxis and treatment].
Vestergaard P; Laursen LC; Schwarz P; Brixen K
Ugeskr Laeger; 2005 Feb; 167(8):898-900. PubMed ID: 15789844
[No Abstract] [Full Text] [Related]
20. [Risk-adapted therapy of osteoporosis. Preventing fractures].
Pfeilschifter J
MMW Fortschr Med; 2001 Nov; 143(47):31-3. PubMed ID: 11791358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
